Difficulty: Medium
Average Score: 79%
Practice
The FDA issued a safety announcement regarding the use of erythropoiesis-stimulating agents (ESAs) in 2010 with the recommendation that:
Correct answer
B
Rationale
The 2010 FDA warning highlighted tumor progression risks in cancer patients on ESAs; renal use continues with caution.